| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
865.33(B) |
| Last
Volume: |
2,837,804 |
Avg
Vol: |
3,271,395 |
| 52
Week Range: |
$434.7 - $891.46 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
1,332,477 |
2,203,227 |
3,639,104 |
6,172,895 |
| Total Sell Value |
$1,114,649,593 |
$1,722,900,173 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
17 |
30 |
51 |
94 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Johnson Kimberly H |
Director |
– • – |
2024-06-17 |
4 |
A |
$885.01 |
$9,735 |
D/D |
11 |
2,654 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2024-06-17 |
4 |
A |
$885.01 |
$9,735 |
D/D |
11 |
2,155 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2024-06-17 |
4 |
A |
$885.01 |
$9,735 |
D/D |
11 |
1,503 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2024-06-17 |
4 |
A |
$885.01 |
$11,505 |
D/D |
13 |
54,138 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2024-06-17 |
4 |
S |
$882.45 |
$172,733,708 |
D/D |
(194,978) |
97,583,810 |
|
0% |
|
| Luciano Juan R |
Director |
– • – |
2024-06-17 |
4 |
A |
$885.01 |
$15,045 |
D/D |
17 |
15,738 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2024-06-14 |
4 |
S |
$882.28 |
$13,256,490 |
D/D |
(15,022) |
97,778,788 |
|
-1% |
|
| Lilly Endowment Inc |
|
– – • |
2024-06-10 |
4 |
S |
$851.69 |
$64,997,274 |
D/D |
(75,510) |
97,793,810 |
|
-2% |
|
| Lilly Endowment Inc |
|
– – • |
2024-06-07 |
4 |
S |
$851.29 |
$118,886,587 |
D/D |
(139,490) |
97,869,320 |
|
-4% |
|
| Lilly Endowment Inc |
|
– – • |
2024-06-06 |
4 |
S |
$836.15 |
$150,485,878 |
D/D |
(179,617) |
98,008,810 |
|
-6% |
|
| Lilly Endowment Inc |
|
– – • |
2024-06-05 |
4 |
S |
$836.14 |
$17,046,673 |
D/D |
(20,383) |
98,188,427 |
|
-6% |
|
| Lilly Endowment Inc |
|
– – • |
2024-06-03 |
4 |
S |
$822.07 |
$159,974,050 |
D/D |
(192,794) |
98,208,810 |
|
-6% |
|
| Norton Johna |
EVP, Global Quality |
• – – |
2024-06-03 |
4 |
AS |
$819.38 |
$5,781,545 |
D/D |
(7,056) |
25,428 |
|
6% |
|
| Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2024-06-03 |
4 |
AS |
$819.47 |
$614,603 |
D/D |
(750) |
7,130 |
|
6% |
|
| Rau Diogo |
EVP & CIDO |
• – – |
2024-06-01 |
4 |
D |
$820.34 |
$2,497,935 |
D/D |
(3,045) |
11,101 |
|
- |
|
| Rau Diogo |
EVP & CIDO |
• – – |
2024-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,300 |
14,146 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2024-05-31 |
4 |
S |
$822.04 |
$18,255,871 |
D/D |
(22,206) |
98,401,604 |
|
-8% |
|
| Lilly Endowment Inc |
|
– – • |
2024-05-29 |
4 |
S |
$809.35 |
$105,747,975 |
D/D |
(130,385) |
98,423,810 |
|
-9% |
|
| Lilly Endowment Inc |
|
– – • |
2024-05-28 |
4 |
S |
$809.00 |
$1,660,068 |
D/D |
(2,052) |
98,554,195 |
|
-9% |
|
| Lilly Endowment Inc |
|
– – • |
2024-05-24 |
4 |
S |
$809.21 |
$74,902,998 |
D/D |
(92,563) |
98,556,247 |
|
-9% |
|
| Lilly Endowment Inc |
|
– – • |
2024-05-23 |
4 |
S |
$804.35 |
$41,120,963 |
D/D |
(50,767) |
98,648,810 |
|
-9% |
|
| Lilly Endowment Inc |
|
– – • |
2024-05-22 |
4 |
S |
$804.18 |
$10,433,483 |
D/D |
(12,974) |
98,699,577 |
|
-10% |
|
| Lilly Endowment Inc |
|
– – • |
2024-05-21 |
4 |
S |
$804.32 |
$150,021,694 |
D/D |
(186,259) |
98,712,551 |
|
-10% |
|
| Luciano Juan R |
Director |
– • – |
2024-05-20 |
4 |
A |
$783.18 |
$14,880 |
D/D |
19 |
15,697 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2024-05-20 |
4 |
A |
$783.18 |
$9,398 |
D/D |
12 |
2,639 |
|
- |
|
343 Records found
|
|
Page 1 of 14 |
|
|
14.50 (1.63%) 
